spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

GE Healthcare opens its first European 3D printing and design center

GE Healthcare Life Sciences

New center in Uppsala, Sweden will apply 3D printing and other techniques to speed up innovation and simplify complex manufacturing processes

CHALFONT ST. GILES, UK and UPPSALA, SWEDEN – 25 September 2017 – GE Healthcare has opened its first 3D printing lab, called the Innovative Design and Advanced Manufacturing Technology Center for Europe, in Uppsala, Sweden. The center will use technologies including 3D printing and robotics to speed up the launch of new innovative products for the healthcare industry.

The center combines advanced manufacturing technology such as metal and polymer printers and collaborative robots, or “cobots”, with traditional machining equipment. A key in realizing the advantages of 3D printing is ensuring the technology is considered at the start of the innovation process with Research and Design teams working with advanced manufacturing engineers and in collaboration with customers. The new center in Uppsala will ensure additive expertise is available from the start of product design. Teams will design, test and produce 3D-printed parts for GE Healthcare products and prepare for final transfer to manufacturing.

Advanced manufacturing techniques like 3D printing can bring significant benefits to manufacturing processes. For example, a 3D printed part can combine 20 parts into a single part and improve performance. Reducing parts in a manufacturing process benefits industries like the biomanufacturing industry where the processes and manufacturing equipment are complex and made up of hundreds different parts.

“We are exploring opportunities where additive can bring cost savings and technical improvements to our supply chain and products” explains Andreas Marcstrom, Manager of Additive Engineering at GE Healthcare’s Uppsala site. “Simply printing a part doesn’t really deliver that much improvement to a product or process. You have to re-think the entire design – to do this, you need your R&D teams and your additive manufacturing engineers working from the start of the development process – our center in Uppsala ensure that critical step.”

GE is working with the biotechnology company Amgen to test the performance of a chromatography column, used in the complex process to develop biopharmaceuticals, a range of drugs used to treat diseases including cancer and immune diseases. The 3D printed column has been custom-designed and is now being tested to see if it can be used in Amgen’s research to help develop improved processes for the purification stage of biopharmaceutical production.

The GE Healthcare Advanced Manufacturing Engineering team have also developed and programmed multiple cobots which are now installed across GE Healthcare factories globally and are improving efficiency in production lines. Many are part of GE Healthcare’s development of Brilliant Factories – plants that combine continuous improvement and digital to operate more efficiently and with higher quality.

The center in Uppsala joins GE Healthcare’s other advanced manufacturing and engineering center which is based in Milwaukee, Wisconsin. The teams in Uppsala will collaborate with those at the Milwaukee center, sharing knowledge and working on new design ideas.

GE Healthcare is one of six GE businesses today using additive applications. GE seeks to grow its new additive business to $1 billion by 2020; GE Additive is planning to sell 10,000 additive machines over the next 10 years.

About Additive Manufacturing
Additive Manufacturing, also known as 3-D printing, has been hailed the fourth industrial revolution because of its potential to improve overall product design, cost, and manufacturing[1]. It works by printing layers of material on top of each other following a digital 3D model. This process makes it less wasteful than traditional subtractive manufacturing in which material is machined off from a material blank to make the final product. The flexibility of additive means the technology is enabling product designs that increase manufacturing efficiency, designs that could not be achieved with traditional manufacturing. Across supply chains, single 3D printed parts are replacing multiple, complex, expensive parts offering technical improvements, waste reduction and cost savings.

About GE Healthcare
GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients. For more information about GE Healthcare, visit our website at www.gehealthcare.com.

[1] Maynard, Andrew D. "Navigating the fourth industrial revolution." Nature nanotechnology 10.12 (2015): 1005.

Media Contact:
GE Healthcare Life Sciences
Sophie White
Communications
T +44 7825582977
E sophie.white@ge.com
phone + 1 800 526 3593
email cs-us@ge.com
web www.gelifesciences.com
email P.O. Box 643065 Pittsburgh, PA 15264-3065 United States of America
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Haselmeier Relies on DQIQOQ Qualified Testing Machines and Zwicks Materials Testing Laboratory

Haselmeier is a leader in the development and manufacture of innovative self injection devices. Numerous international pharmaceutical manufacturers are customers of this Swiss company. In addition to testing production batches of pen injectors, Zwick's Materials Testing Laboratory offers DQ/IQ/OQ qualification and measurement system analysis of the testing system used for the tests.
More info >>


White Papers

Driving ROI: The Case for Investing in Contract & Site Regulatory Document Management Services

DrugDev

With tight timelines and complicated regulatory documentation requirements, getting a clinical trial up and running quickly is easier said than done. Key milestones can be achieved only after the successful negotiation of clinical trial agreements and completion of essential regulatory documents. Many clinical trials are hindered by inefficient, labor-intensive processes. Prolonged, inefficient activation can hamper investigator satisfaction and, ultimately, have a negative bottom-line impact for sponsors and CROs. In addition, the Sunshine Act is heightening the importance of financial disclosure in clinical trials. Without a robust financial disclosure strategy, sponsors cannot ensure that physician self-reported financial disclosure data are aligned with the payment data being reported through the Sunshine Act, increasing financial and regulatory risk.
More info >>

Industry Events

6th Annual Single Cell Analysis Congress

8-9 November 2018, London, UK

Oxford Global is proud to present its 6th Annual Single Cell Analysis Congress taking place on 8-9 November 2018 in London.  Part of the Genomics & Synthetic Biology Series UK, the congress will bring together over 600 end users representing internationally renowned research & academic institutions, clinical research institutions, healthcare organisations as well as leading pharmaceutical and biotech companies.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement